Accelerating GLP-1 Peptide Development: A Webinar on Integrated Formulation Strategies

The landscape of diabetes and obesity treatment is increasingly being transformed by GLP-1 peptide therapeutics. As the demand for effective therapies rises, professionals in the pharmaceutical industry are seeking innovative approaches to expedite the development of these vital medications. This urgency is highlighted by an upcoming webinar hosted by Xtalks, titled "Accelerating GLP-1 Peptides to Market Through Integrated Formulation & Analytical Development."

The webinar will dive into how formulation decisions are pivotal in shaping Critical Quality Attributes (CQAs) of GLP-1 peptides. Attendees will learn about the significance of comprehensive analytical data in developing robust control strategies that ensure both efficacy and safety of drug products. By integrating formulation science with analytical strategy, participants can gain insights that will accelerate their path toward CMC (Chemistry, Manufacturing, and Controls) readiness and help navigate regulatory requirements effectively.

Understanding the Challenges

As global programs progress from early development to commercialization, various unique challenges arise with GLP-1 drug products. These include issues related to peptide stability, solubility, aggregation behavior, viscosity control, device compatibility, and manufacturability. Addressing these complexities requires a systematic formulation design, supported by scientifically valid analytical control strategies. The webinar will shed light on contemporary formulation approaches, including methods for excipient selection, fatty acid conjugation, and strategies for optimizing solubility and viscosity suited for injectable delivery systems.

Case studies of already marketed therapies, such as liraglutide, semaglutide, and tirzepatide, will provide real-world context for the discussions, bridging the gap between theory and practice.

Advanced Analytical Characterization Tools

A significant part of the webinar will be dedicated to advanced analytical characterization tools that play a critical role in managing quality and lifecycle of GLP-1 peptides. Experts will discuss techniques such as LC-MS, SEC-MALS, surface plasmon resonance (SPR), peptide mapping, cell-based bioassays, and stability-indicating methods, all while considering both scientific and regulatory perspectives. By demonstrating how connected analytical data informs CQAs, the session aims to strengthen participants’ ability to develop effective control strategies and bolster CMC documentation during global regulatory submissions.

Registration Details

This engaging webinar presents an excellent opportunity for professionals in the pharmaceutical and biotechnology fields to align their formulation decisions with analytical evidence, thereby enhancing product consistency, scalability, and compliance throughout all development phases.

Join the experts from OneSource Specialty Pharma, including M.S. Vijaykanth PhD, Senior Vice President and Head of Research & Development, and Nandakumar Sundaramoorthy PhD, Director and Head of the Analytical Development Department, on Wednesday, April 15, 2026, at 11 am EDT (5 pm CEST).

For further details or to register for this insightful event, please visit the official Xtalks website.

Xtalks is a reputable platform empowering professionals across pharma, biotech, medtech, healthcare, and research with essential knowledge and collaborative insights that propel the industry forward. Sign up today to secure your spot in this timely and informative webinar that could redefine your approach to GLP-1 peptide development.

Conclusion

In conclusion, the upcoming webinar presents a prime opportunity for professionals in the field to tap into collective knowledge and best practices regarding GLP-1 peptide development. Engaging with key thought leaders and exploring integrated formulation and analytical strategies could elevate your understanding of this rapidly evolving sector, ultimately contributing to efficient market readiness of advanced therapeutic solutions for diabetes and obesity.